Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Tech Master who wrote (505)	5/4/1998 12:29:00 PM
From: Tom R. Clarksburg	Read Replies (4) \| Respond to of 2135

What Entremed has discovered is nothing new. A drug called Thalidomide which has been around for over 30 years but banned in this country because of the horrific birth defects seen in European in Brazilian new borns. Pure , clinical grade Shark cartilage has also been tested in clinical trials in several leading U.S. and worldwide hospitals with tremendous preliminary results. Therefore the science of "anti-angiogenesis" is nothing new, but the first company to apply it will get worldwide recognition. The Drug, Thalidomide, was approved in the U.S. for several applications about a year ago. I believe Bristol Myers was the company that was given the right to manufacture Thalidomide. Shark Cartilage, that is clinical grade, is produced by a small non-public company called LANE LABS. Lane labs is headed my Dr. Lane, a man who has researched the anti-angiogenic characteristics of Shark Cartilage since the remarkable studies done in Cuba in the 1994-1995 which appeared on a segement in CBS's 60 Minutes back in 1995. Regards TOM